NASDAQ:KYTX

Kyverna Therapeutics Stock News

Healthcare > Biotechnology

Buy KYTX

*Your capital is at risk

$7.82

-0.0800 (-1.01%)

At Close: Jun 03, 2026

Kyverna Therapeutics Highlights Updated Miv-cel Data at EULAR Demonstrating Substantial Reduction in Disease Activity in ACPA-Positive, Treatment Refractory Rheumatoid Arthritis

08:00am, Wednesday, 03'rd Jun 2026

Majority of patients met the American College of Rheumatology improvement criteria (ACR70) response by Week 36 Single-dose of miv-cel delivered deep B-cell depletion with evidence of immune reset Miv-

Kyverna Therapeutics Names Greg Martini as Chief Financial Officer

08:00am, Monday, 18'th May 2026

Veteran biopharma leader joins to help lead Kyverna's next phase of commercial growth Veteran biopharma leader joins to help lead Kyverna's next phase of commercial growth

Kyverna Therapeutics to Present at Upcoming Investor Conferences

08:00am, Thursday, 14'th May 2026

EMERYVILLE, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a late-stage clinical biopharmaceutical company focused on developing cell therapies for patients with a

Kyverna Therapeutics Announces Initiation of Rolling SPS BLA Submission and Reports First Quarter 2026 Financial Results

04:02pm, Tuesday, 12'th May 2026

Positive pre-BLA meeting with FDA alignment reached on KYSA-8 single-arm trial in stiff person syndrome (SPS); rolling BLA submission initiated

Kyverna Therapeutics Appoints Nadia Dac, Seasoned Commercial Leader in Neurology and Rare Disease, as Chief Commercial Officer

08:00am, Monday, 04'th May 2026

EMERYVILLE, Calif., May 04, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a late-stage clinical biopharmaceutical company focused on developing cell therapies for patients with a

Kyverna Therapeutics Showcases miv-cel Data in SPS, gMG; CEO Eyes First Autoimmune CAR-T BLA

01:06am, Monday, 27'th Apr 2026

Kyverna Therapeutics (NASDAQ: KYTX) highlighted new clinical data for its CD19-directed autologous CAR T-cell therapy mivocabtagene autoleucel (miv-cel), formerly KYV-101, during an American Academy o

Kyverna Therapeutics: 'Strong Buy' On Additional POC Of Miv-Cel In Myasthenia Gravis

03:31pm, Wednesday, 22'nd Apr 2026

Kyverna Therapeutics maintains a "Strong Buy" rating, driven by positive clinical data and upcoming regulatory milestones for miv-cel. Miv-cel achieved statistically significant endpoints in SPS and d

Kyverna Presents Registrational Trial Primary Analysis for Miv-cel in Stiff Person Syndrome Demonstrating Statistically Significant, Durable Clinical Benefit Across All Endpoints in an Oral, Late-Breaker Session at AAN Annual Meeting

06:45pm, Tuesday, 21'st Apr 2026

Single-dose of miv-cel achieved robust and durable improvements in mobility, reversed disability scores, and eliminated the need for chronic immunotherapies – outcomes not previously observed in SPS

Kyverna Therapeutics Positive Phase 2 Readout: Deep Responses, But Very Small Sample

07:30am, Tuesday, 21'st Apr 2026

Kyverna Therapeutics reported robust early Phase 2 miv-cel data in gMG, showing 100% response rates and deep, durable clinical improvements. KYTX's miv-cel offers rapid onset, potential for treatment-

Kyverna Presents Longer-Term Phase 2 Data for Miv-cel in Generalized Myasthenia Gravis at AAN, Demonstrating Deep, Durable Responses through 52 Weeks

08:00am, Monday, 20'th Apr 2026

100% of patients achieved rapid, sustained improvements across MG-ADL and QMG at 24 weeks, further increasing confidence in Phase 3 trial

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by